Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics

Clinical Pharmacokinetics

Volumn 45, Issue 6, 2006, Pages 633-644

  Swaisland, Helen C ^a   Cantarini, Mireille V ^a   Fuhr, Rainard ^b   Holt, Alison ^a  

^a ASTRAZENECA   (United Kingdom)

^b PAREXEL INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; GEFITINIB; MIDAZOLAM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; GENETIC ANALYSIS; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; AGED; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; MALE; MIDAZOLAM; MIDDLE AGED; PHENOTYPE; QUINAZOLINES;

EID: 33745899929     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645060-00006     Document Type: Article

References (27)

1. Frampton JE, Easthope SE. Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer. Drugs 2004; 64: 2475-92
2. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-46
3. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58
4. Thatcher N, Chang A, Parikh P, et al. Results of a Phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care (BSC) in patients with advanced non-small-cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens [abstract LB-L6]. Proceedings of 96th Annual Meeting of American Association for Cancer Research (AACR); 2005 Apr 16-20; Anaheim/Orange County (CA)
5. Botwood N, Caroll K, Thatcher N. A double blind, placebo controlled, parallel group, multicentre, randomised phase III survival study comparing ZD1839 (IRESSA™) [250mg tablets] plus best supportive care versus placebo plus best supportive care in patients with advanced NSCLC who have received one or two prior chemotherapy regimens and are refractory or intolerant to their most recent regimen. AstraZeneca Study Number D7913C00709. Macclesfield, UK: AstraZeneca; 2005 Jun 6
6. Swaisland HC, Smith RP, Laight A, et al. Single-dose clinical pharmacokinetic studies of gefitinib (IRESSA, ZD1839), an oral epidermal growth factor receptor tyrosine kinase inhibitor. Clin Pharmacokinet 2005; 44 (11): 1165-77
7. Averbuch S, Swaisland H, Wolf M, et al. ZD1839 (IRESSA™) New drug application. Item 6. Human pharmacokinetics and bioavailability. 2001 Dec 5
8. Gibbs MA, Hosea NA. Factors affecting the clinical development of cytochrome P450 3A substrates. Clin Pharmacokinet 2003; 42: 969-84
9. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171-84
10. McKillop D, McCormick AD, Millar A, et al. Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 2005; 35: 39-50
11. Von Moltke LL, Greenblatt DJ, Schmider J, et al. Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995; 29 Suppl. 1: 33-44
12. Wandel C, Bocker RH, Bohrer H, et al. Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally. Drug Metab Dispos 1998; 26: 110-4
13. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo corre-lations in liver transplant patients. J Pharmacol Exp Ther 1994; 271: 549-56
14. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-9
15. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterisation of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91
16. Sachse C, Brockm̈oller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-95
17. Kivisto KT, Kroemer HK. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 1997; 37: 40S-8S
18. Laight A. An open, two period, single centre phase I trial to determine the multiple dose pharmacokinetics of ZD1839 following administration over a 14-day period to healthy male volunteers and to assess the effects of a loading dose regimen on the time to reach steady state. AstraZeneca Trial Number 1839IL/0034. Macclesfield, UK: AstraZeneca; 2000 Nov 27
19. Swaisland HC, Ranson M, Smith RP, et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005; 44 (10): 1067-81
20. Swaisland H, Laight A, Stafford L, et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 2001; 40: 297-306
21. Jones HK, Stafford LE, Swaisland HC, et al. A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in phase I clinical trials. J Pharm Biomed Anal 2002; 29: 221-8
22. Zaigler M, Tantcheva-Póor I, Fuhr U. Problems and perspectives of phenotyping for drug-metabolizing enzymes in man. Int J Clin Pharmacol Ther 2000; 38: 1-9
23. Goh BB-C, Lee S-C, Wang L-Z, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 3683-90
24. Hirth J, Watkins PB, Strawderman M, et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6: 1255-8
25. Lown KS, Thummel KE, Benedict PE, et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995; 57: 16-24
26. Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243-72
27. Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA™) monotherapy: clinical experience in non-small-cell lung cancer. Drug Saf 2004; 27: 1081-92